Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07407933 · ClinicalTrials.gov registry record · Phase 1
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by MediLink Therapeutics (Suzhou) Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 118
- Enrollment target
NCT07407933: Recruiting Phase 1 study, sponsored by MediLink Therapeutics (Suzhou) Co..
NCT07407933 is a Phase 1 study that is actively recruiting participants, run by MediLink Therapeutics (Suzhou) Co.. The registered enrollment target is 118 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07407933, a Phase 1 study, is actively recruiting participants, sponsored by MediLink Therapeutics (Suzhou) Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 118 participants
- Enrollment target
Study Summary
This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the safety and tolerability of YL201 in combination with fixed dose of atezolizumab. The planned dose levels of YL201 are 1.2 mg/kg, 1.6 mg/kg and 2.0 mg/kg. Part 2 consists of a dose optimization stage followed by a dose expansion stage. During the dose optimization stage, participants will be randomized 1:1:1 to receive either YL201 at 1.2 mg/kg,1.6 mg/kg or 2.0 mg/kg Q3W in combination with fixed dose of atezolizumab. The decision to initiate the dose expansion stage in Part 2 and choose one or two of the YL201 dose level(s) will be based on the review of safety, PK, and efficacy from the dose optimization stage. Treatment will continue until disease progression, unacceptable toxicity, or withdraw of consent.
Interventions
- DRUG Atezolizumab
- DRUG YL201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2026-03-31 |
| Est. Completion | 2029-02 |
| Phase | Phase 1 |
What NCT07407933 shows while recruiting
NCT07407933 is an interventional study that assigns participants to a tested intervention. The registered 118 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% higher).
The record links to 0 conditions, and to 2 interventions - of which Atezolizumab is the first listed.
NCT07407933 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07407933 about?
NCT07407933 is a clinical study titled "A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors". This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the safety and tolerability of YL201 in combination with fixed dose of ate...
What is the current status of trial NCT07407933?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 118 participants. The study started on 2026-03-31. Estimated completion is 2029-02.
What interventions are being tested in trial NCT07407933?
The interventions under investigation include: Atezolizumab (DRUG), YL201 (DRUG).
Who is sponsoring clinical trial NCT07407933?
This trial is sponsored by MediLink Therapeutics (Suzhou) Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07407933's enrollment target sits among peer trials
118 499th of 2000 higher than 1,502 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821623 · 118 participants · Phase 2
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
- NCT04040959 · 118 participants · Phase 2
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
- NCT04696029 · 118 participants · Phase 2
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
- NCT05223192 · 118 participants · NA
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI